ADMA Biologics, Inc.

ADMA · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.0%

Institutions93.3%

Public / Other

	You	Peer avg
P/E	13.7	83.7
Revenue Growth	+15.9%	+22.5%
ROE	41.9%	-135.9%

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$510.17M	$426.45M	$258.21M	$154.08M	$80.94M	$42.22M	$29.35M	$16.99M	$22.76M	$10.66M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$217.41M	$206.90M	$169.27M	$118.81M	$79.77M	$61.29M	$39.50M	$42.19M	$29.16M	$6.36M
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$292.76M	$219.55M	$88.94M	$35.27M	$1.17M	–	–	–	–	–
Gross profit as a percentage of revenue.	57.4%	51.5%	34.4%	22.9%	1.4%	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$191.44M	$138.98M	$21.63M	-$39.37M	-$58.37M	-$64.91M	-$41.42M	-$60.29M	-$39.31M	-$17.33M
Operating income as a percentage of revenue.	37.5%	32.6%	8.4%	-25.5%	-72.1%	-153.8%	-141.1%	-354.9%	-172.7%	-162.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$146.93M	$197.67M	-$28.24M	-$65.90M	-$71.65M	-$75.75M	-$48.28M	-$65.74M	-$43.76M	-$19.52M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.62	$0.85	$0.00	$0.00	$-0.51	$-0.88	$0.00	$-1.00	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.60	$0.81	$0.00	$0.00	$-0.51	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$87.63M	$103.15M	$51.35M	$86.52M	$51.09M	$55.92M	$26.75M	$22.75M	$43.11M	$9.91M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$624.24M	$488.68M	$329.18M	$348.46M	$276.25M	$207.67M	$127.09M	$88.88M	$108.02M	$23.69M
All of the company's interest-bearing borrowings, short and long term combined.	$72.14M	–	–	–	–	–	–	–	$0	$6.11M
Everything the company owes — debt, unpaid bills, and other obligations.	$146.92M	$139.66M	$193.98M	$196.49M	$135.08M	$119.42M	$100.90M	$69.11M	$67.69M	$28.14M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$477.32M	$349.02M	$135.21M	$151.97M	$141.17M	$88.25M	$26.19M	$19.77M	$40.33M	-$4.46M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$50.40M	$118.67M	$8.80M	-$59.51M	-$112.37M	-$102.00M	-$76.19M	-$62.68M	-$37.27M	-$18.27M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$22.57M	$8.23M	$4.77M	$13.91M	$13.51M	$12.73M	$3.81M	$2.10M	$2.68M	$73410
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$27.82M	$110.45M	$4.03M	-$73.42M	-$125.88M	-$114.73M	-$80.01M	-$64.77M	-$39.95M	-$18.34M

ADMA Biologics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison

Income Statement

Balance Sheet

Cash Flow Statement